Company Filing History:
Years Active: 2007
Title: Innovative Contributions of Annette Cornelia Bakker in the Field of Cell Cycle Regulation
Introduction: Annette Cornelia Bakker, located in Borgerhout, Belgium, is an innovative inventor known for her significant contributions to the field of pharmacology. With one patent to her name, she has demonstrated remarkable expertise in developing compounds that function as kinase inhibitors.
Latest Patents: Annette Bakker's notable patent is titled "3-furanyl analogs of toxoflavine as kinase inhibitors." This invention discusses compounds that include N-oxide forms, pharmaceutically acceptable addition salts, and stereochemically isomeric forms. The primary focus of her invention is to serve as inhibitors of cyclin-dependent serine/threonine kinases (Cdks), as well as kinases and phosphatases involved in cell cycle regulation. This includes targeting tyrosine kinases such as Wee1, Mik1, and Myt1, in addition to tyrosine dephosphatases like Cdc25 and Pyp3. The patent also covers pharmaceutical compositions comprising these compounds and outlines methodologies for treating cell proliferative disorders, including atherosclerosis, restenosis, and cancer.
Career Highlights: Annette is associated with Janssen Pharmaceutica NV, a prominent name in the pharmaceutical sector. Her innovative approach to drug development emphasizes her skills in addressing critical health issues through scientific research and patenting.
Collaborations: Throughout her career, Annette Bakker has collaborated with esteemed colleagues, including Jean Fernand Armand Lacrampe and Richard William Connors. These partnerships highlight her ability to work effectively within a team-centric environment, contributing to advancements in medical research.
Conclusion: Annette Cornelia Bakker exemplifies the role of an innovative inventor in modern science. With her patent focusing on vital mechanisms in cell cycle regulation and treatment of serious health conditions, she continues to pave the way for future medical breakthroughs. Her work at Janssen Pharmaceutica NV, combined with collaborations with fellow researchers, positions her as a key figure in the ongoing quest for medical advancements.